The drugmaker Eli Lilly & Co. has agreed to pay up to $500 million to settle approximately 18,000 claims related to its atypical antipsychotic Zyprexa (olanzapine). Most of the claims stated that, before September 2003, the Zyprexa package insert did not adequately display the risk of hyperglycemia and diabetes.
…
Simone Roberts
ZYPREXA (olanzapine) has been found to be more effective than lithium in helping people who suffer from bipolar disorder to remain in remission and prevent relapse into mania, according to a study published in a recent issue of the American Journal of Psychiatry .
The year-long study showed that in the maintenance t…
A former consultant to Eli Lilly & Co. has agreed to pay the drug maker $100,000 to settle complaints that he leaked confidential information about Zyprexa (olanzapine) to a plaintiffs’ attorney. Dr. David Egilman was an expert witness for the plaintiffs in Zyprexa product li…
The Texas Medicaid agency announced that it will not include the atypical antipsychotic Zyprexa (olanzapine) on its preferred drug list. To prescribe Zyprexa to Medicaid patients, physicians will now have to get prior authorization from the agency. Texas, similar to many other states, is facing budget constraints; Zyprexa accounted for $86 million of Texas Medicaid’s $1.9 billion in drug spending last year.
Related Results
…
Eli Lilly and Company would like to inform you of important labeling changes regarding Zyprexa (olanzapine). The Food and Drug Administration (FDA) has asked all manufacturers of atypical antipsychotic medications, including Lilly, to add a Warning statement describing the increased…
Business Editors/Health/Medical Writers
INDIANAPOLIS–(BUSINESS WIRE)–Sept. 17, 2003
Eli Lilly and Company (NYSE:LLY) has received a letter from the U.S. Food and Drug Administration (FDA) requesting updated product labeling for all atypical antipsychotics, to include a warning about additional information on hyperglycemia and diabetes. In addition to Zyprexa(R) (olanzapine), the atypical antipsychotic class includes Clozaril(R) (clozapine, Novartis), Risperda…
RAMAT GAN, Israel — Obecure has conducted the first initiation visit for its Phase II clinical trial to evaluate the efficacy of the company’s OBE101 drug candidate for prevention of weight gain in patients treated with Zyprexa, (olanzapine) an antipsychotic medication. The study is a double-blinded, placebo-controlled multicenter trial in about 78 subjects over a period of four months. The study, approved by Health Canada and the central IRB, will be conducted at several psychi…
Date: April 14, 2005
For Release: Immediately
Refer to: (317) 276-2506 - Phil Belt
(317) 276-5795 - Terra Fox
U.S. District Court Rules in Favor of Lilly;
Upholds Company’s 2011 Patent on Zyprexa
The U.S. District Court for the Southern District of Indiana today upheld Eli
Lilly and Company’s (NYSE: LLY) 2011 patent on ZyprexaA’, a breakthrough
medici…
SIDE EFFECTS OF LILLY’S ZYPREXA are the topic of an interview with a former sales rep posted to YouTube by PharmedOut, a non-profit funded by money from the Neurontin settlement. “We were instructed by our DMs to downplay those side effects, to focus on the efficacy of the d…
